Objective To review the research progress of C terminal propeptide of collagen type II (CTX-II), a osteoarthritis (OA) biomarker. Methods Domestic and international l iterature about CTX-II was reviewed extensively and summarized. Results CTX-II is investigated broadly and has the best performance of all currently available biomarkers. CTX-II is a truly useful biomarker for early diagnosis, prognosis, and measurement of treatment response in OA. Conclusion Single CTX-II may be not sufficient for early diagnosis and prognosis of OA, so a combination of CTX-II and other biomarkers or diagnosis methods is needed.
ObjectiveTo explore the predictive effect of the femoral neck strength composite indexes on femoral head collapse in non-traumatic osteonecrosis of the femoral head (ONFH) compared with bone turnover marker.MethodsThe non-traumatic ONFH patients who were admitted and received non-surgical treatment between January 2010 and December 2016 as the research object. And 96 cases (139 hips) met the selection criteria and were included in the study. There were 54 males (79 hips) and 42 females (60 hips), with an average age of 40.2 years (range, 22-60 years). According to whether the femoral head collapsed during follow-up, the patients were divided into collapsed group and non-collapsed group. The femoral neck width, hip axis length, height, body weight, and bone mineral density of femoral neck were measured. The femoral neck strength composite indexes, including the compressive strength index (CSI), bending strength index (BSI), and impact strength index (ISI), were calculated. The bone turnover marker, including the total typeⅠcollagen amino terminal elongation peptide (t-P1NP), β-crosslaps (β-CTx), alkaline phosphatase (ALP), 25 hydroxyvitamin D [25(OH)D], and N-terminal osteocalcin (N-MID), were measured. The age, gender, height, body weight, body mass index (BMI), bone mineral density of femoral neck, etiology, Japanese Osteonecrosis Investigation Committee (JIC) classification, femoral neck strength composite indexes, and bone turnover marker were compared between the two groups, and the influencing factors of the occurrence of femoral head collapse were initially screened. Then the significant variables in the femoral neck strength composite indexes and bone turnover marker were used for logistic regression analysis to screen risk factors; and the receiver operating characteristic (ROC) curve was used to determine the significant variables’ impact on non-traumatic ONFH. ResultsAll patients were followed up 3.2 years on average (range, 2-4 years). During follow-up, 46 cases (64 hips) had femoral head collapse (collapsed group), and the remaining 50 cases (75 hips) did not experience femoral head collapse (non-collapsed group). Univariate analysis showed that the difference in JIC classification between the two groups was significant (Z=–7.090, P=0.000); however, the differences in age, gender, height, body weight, BMI, bone mineral density of femoral neck, and etiology were not significant (P>0.05). In the femoral neck strength composite indexes, the CSI, BSI, and ISI of the collapsed group were significantly lower than those of the non-collapsed group (P<0.05); in the bone turnover marker, the t-P1NP and β-CTx of the collapsed group were significantly lower than those of the non-collapsed group (P<0.05); there was no significant difference in N-MID, 25(OH)D or ALP between groups (P>0.05). Multivariate analysis showed that the CSI, ISI, and t-P1NP were risk factors for femoral collapse in patients with non-traumatic ONFH (P<0.05). ROC curve analysis showed that the cut-off points of CSI, BSI, ISI, t-P1NP, and β-CTx were 6.172, 2.435, 0.465, 57.193, and 0.503, respectively, and the area under the ROC curve (AUC) were 0.753, 0.642, 0.903, 0.626, and 0.599, respectively. ConclusionThe femoral neck strength composite indexes can predict the femoral head collapse in non-traumatic ONFH better than the bone turnover marker. ISI of 0.465 is a potential cut-off point below which future collapse of early non-traumatic ONFH can be predicted.
This study aims to predict expression of Ki67 molecular marker in pancreatic cystic neoplasm using radiomics. We firstly manually segmented tumor area in multi-detector computed tomography (MDCT) images. Then 409 high-throughput features were automatically extracted and the least absolute shrinkage selection operator (LASSO) regression model was used for feature selection. After 200 bootstrapping repetitions of LASSO, 20 most frequently selected features made up the optimal feature set. Then 200 bootstrapping repetitions of support vector machine (SVM) classifier with 10-fold cross-validation were used to avoid overfitting and accurately predict the Ki67 expression. The highest prediction accuracy could achieve 85.29% and the highest area under the receiver operating characteristic curve (AUC) was 91.54% with a sensitivity (SENS) of 81.88% and a specificity (SPEC) of 86.75%. According to the results of experiment, the feasibility of predicting expression of Ki67 in pancreatic cystic neoplasm based on radiomics was verified.
The nucleic acid adapters of tumor serum markers are oligonucleotide molecules with high specificity and high affinity with tumor serum markers obtained by in vitro screening with systematic evolution of ligands by exponential enrichment (SELEX). Researchers take the advantage of the nucleic acid adapter to explore new tumor serum markers that have more diagnostic value for tumor diagnosis. Recently, some achievements have been achieved in the research of liver cancer and stomach cancer. This paper has reviewed nucleic acid adapter and its research in the serum tumor marker screening, and discussed the value of the nucleic acid adapter of serum tumor markers in the diagnosis, as well as current problems existing in the research. This paper is very useful to help people better understand the screening of nucleic acid adapters of tumor serum markers, and to provide help in discovering new tumor serum markers.
Objective To select relatively specific biomarkers in serum from lung adenocarcinoma patients using surface-enhanced laser desorption ionization time of flight mass spectrometry （SELDI-TOF-MS） Protein Chip technology, and study the follow-up results of postoperative serum proteomic patterns. Methods Serum samples from 71 lung adenocarcinoma patients. 71 healthy volunteers with matched gender, age and history of smoking were analyzed by using weak cation exchange 2（WCX2） Protein Chip to select potentially biomarkers. Seventy-one patients were followed-up till 9 months after surgery. Compare the serum proteomic patterns 3,6 and 9 months after surgery. Results Five highly expressed potential biomarkers were identified with the relative molecular weights of 4 047.79, 4 203. 99, 4 959. 81, 5 329. 30 and 7 760. 12 Da. The postoperative serum proteomic patterns changed among individuals, and correlated with patients＇ clinical stage. Conclusions SELDI-TOF-MS Protein Chip technology is a quick, easy, convenient, and high-throughout analyzing method capable of selecting relatively specific, potential biomarkers from the serum of lung adenocarcinoma patients and may have attractive clinical value.
【摘要】 目的 探討炎性標志物高敏C反應蛋白(highsensitivity creaction protein ,hsCRP)、纖維蛋白原(fibrinogen, FIB)與P波離散度(P wave dispersion, PWD)的關系。 方法 回顧分析2005年1〖CD3/5〗8月收治的102例心臟病住院患者的臨床資料,分別測量PWD和獲得hsCRP、FIB血濃度,對比分析炎性標志物和PWD之間的關系。 結果 心臟病住院患者的PWD (408±93) ms、hsCRP (368±317) mg/L和FIB (411±294) g/L均較正常值高。PWD異常組和正常組的血hsCRP分別為(482±211)、(193±093) mg/L,差異有統計學意義(Plt;001)；血FIB分別為(510±348)、(251±129) g/L,差異有統計學意義(Plt;005)。血hsCRP增高組PWD(549±96) ms，較正常組(285±74) ms顯著增大(Plt;001),血FIB增高組PWD(479±68) ms，較正常組(359±87) ms顯著增大(Plt;005)。PWD與血hsCRP成正相關(相關系數R=0418,Plt;005)；PWD與血FIB成正相關(相關系數R=0292,Plt;005)。 結論 PWD與血炎性標志物密切相關,血炎性標志物增高的患者PWD增大。【Abstract】〓Objective〓〖WT5”BZ〗To investigate the relationship between P wave dispersion (PWD) and inflammatory marker (serum highsensitivity creaction protein, hsCRP and fibronogen,FIB). Methods Retrospectively measure PWD of 102 inpatients with heart diseases,and get the results of the hsCRP and FIB. Results The average PWD (408±93) ms of 102 inpatients is higher than normal value,the average hsCRP (368±317) mg/L and FIB (411±294) g/L are higher than normal value. The serum concentration of the hsCRP and FIB increase significantly in abnormal PWD subgroup than normal PWD subgroup, respectively [(482±211) mg/L vs (193±093) mg/L, Plt;001 and (510±348) g/L vs (251±129) g/L, Plt;005)]. The PWD of the serum highconcentration hsCRP and FIB subgroup increase than normalconcentration subgroup significantly, respectively [(549±96) ms vs (285±74) ms, Plt;001 and (479±68) ms vs (359±87) ms,Plt;005] PWD has positive relationship with hsCRP(R=08,Plt;005)and FIB (R=0292,Plt;005). Conclusions PWD has good relationship with serum inflammtory makers, PWD increases with the ascending of concentration of the serum hsCRP and FIB.
ObjectiveTo investigate the value of plasma microRNA-216 (miR-216) in patients with acute pancreatitis as a clinical biomarker to early identify severe acute pancreatitis (SAP).MethodsPatients with acute pancreatitis who admitted to the hospital within 48 hours after the onset of disease between September and November 2014 were enrolled in this study. Plasam and clinical data of all the patients were collected. MiR-216 in the plasma was detected using quantitative real time-polymerase chain reaction.ResultsA total of 25 patients were enrolled. The Ct value of plasma miR-216 in SAP patients (32.40±1.43) was significantly upregulated than mild acute pancreatitis (MAP) (35.85±1.91, P<0.05) and moderately severe acute pancreatitis (MSAP) patients (35.90±2.44,P<0.05), respectively. The area under receiver operating characteristic curve for plasmamiR-216 in predicting SAP was 0.792 (P<0.05), which did not differ much from other conventional parameters such as C-reactive protein, urinary nitrogen, and cytokines (P>0.05).ConclusionPlasma miR-216 is significantly upregulated in SAP patients compared with MAP and MSAP, but it shows no inferior efficiency than the investigated conventional predictors in predicting SAP.
Metaiodobenzylguanidine (MIBG) is an analog of norepinephrine that accumulates in sympathetic nerve endings soon after intravenous administration. The degree of accumulation reflects the uptake, storage and release of transmitters by noradrenergic neurons. Myocardial imaging with 123I labeled MIBG (123I-MIBG) can be used to estimate the extent of local myocardial sympathetic nerve damage, which has been widely used in the diagnosis and treatment of various heart diseases. In recent years, numerous studies have been carried out on the application of 123I-MIBG in the diagnosis of degenerative diseases of the nervous system (such as Parkinson's disease and dementia of Lewy body), and have made some achievements. The purpose of this review is to summarize the current clinical application of 123I-MIBG myocardial imaging in the diagnosis of dementia with Lewy bodies, the problems in imaging technology and the possible research directions in the future, so as to provide valuable reference information for clinicians to reasonably and accurately apply this technology in the early diagnosis and discrimination of dementia.
Objective
The aim of this study is to review the relationship between microRNA (miR)-200a and the proliferation, metastasis, and prognosis of hepatocellular carcinoma (HCC) based on the previous relevant studies.
Methods
A systematic literature search was performed to identify the related studies. We summarized the expression level of miR-200a in HCC, its roles and mechanisms in proliferation, metastasis, and prognosis of HCC.
Results
The expressions of miR-200a were down-regulated in HCC tissue, cell, and patients’ serum. The normal expression or the overexpression of miR-200a could significantly inhibite the proliferation, invision, and metastasis of HCC. Moreover, the differentially expressed miR-200a in the tumor tissue or the patient’ serum was potentially valuable for the early diagnosis and prognostic predicting of HCC. Although there had been many advances on miR-200a in HCC, only a few biological functions had been identified. The underlying regulating mechanisms and more targeted genes of miR-200a still needed to be further studied.
Conclusion
miR-200a not only has an inhibitory effect on the proliferation, invasion, and metastasis of HCC, but also has a certain clinical application value in the early diagnosis and prognosis of HCC.
ObjectiveThe aim of this meta-analysis and systematic review is to assess the effectiveness of microRNAs as a diagnostic tool for individuals with epilepsy. MethodsA systematic search of PubMed, EMBASE, the Cochrane Library, and Web of Science databases was performed to collect literature on miRNA diagnosis of epilepsy up to January 1, 2024. Two researchers independently screened and extracted the literature and resolved discrepancies by negotiation. The QUADAS-2 evaluation tool was used to assess the quality of the included studies. Statistical analysis was performed using Review Manager 5.4, Meta-Disc 1.4, and Stata 17.0. Results A total of 17 papers were included, including 942 patients with epilepsy and 932 healthy controls. miRNA in the diagnosis of epilepsy had a combined sensitivity of 0.76 [95%CI (0.71, 0.79)], combined specificity of 0.78 [95%CI (0.74, 0.82)], and area under the SROC curve of 0.84 [95%CI (0.80, 0.87)]. Subgroup analysis showed that miRNA had higher diagnostic value for temporal lobe epilepsy, especially medial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). ConclusionThe study suggests that miRNA may be a promising tool for the diagnosis of epilepsy, especially temporal lobe epilepsy, but more high-quality studies are needed to support it.
